Compounding Guidance

503A Pharmacy (Office-Compounding):

• Veterinarian in-clinic or pharmacy compounds small quantities
• Limited to immediate patient needs (typically 30-day supply)
• No advertising or mass-production
• Pharmacist or trained veterinary staff must perform compounding
• Lower regulatory burden; suitable for single-patient formulations
• Examples: methimazole transdermal for cats, potassium bromide flavored suspension

503B Pharmacy (Outsourced Compounding):

• Specialized outsourced facility compounds for multiple veterinarians
• Must register with FDA, comply with cGMP standards
• Can compound larger quantities
• Higher quality assurance and stability testing
• Used for commercially unavailable products (e.g., cisapride), complex formulations

Common Indications for Compounding

• Pediatric Dosing: Commercially available doses exceed neonatal requirements (e.g., reduced doxycycline for puppies)
• Discontinued Products: Cisapride (gastrokinetic agent), tramadol suspension, certain antibiotics
• Transdermal Formulations: Methimazole for hyperthyroid cats (avoids PO dosing challenges)
• Flavor Masking: Antibiotics, anticonvulsants for feline patients (cats reject bitter compounds)
• Unusual Routes: Suspensions from tablets, specialized topical formulations
• Dose Customization: Rare genotype-based dosing adjustments (e.g., MDR1 sensitivity)

Commonly Compounded Veterinary Drugs

Workflow for Compounding Decisions

1. Verify VCPR: Establish valid client-patient relationship and confirm clinical need documented in medical record
2. Check Availability: Confirm no FDA-approved equivalent exists or is unsuitable (dose, formulation, species)
3. Risk-Benefit Assessment: Is compounding justified given quality uncertainty vs. clinical benefit?
4. Pharmacy Selection: 503A (immediate, simple) or 503B (complex, documented stability)?
5. Prescription Specifications:
   • Drug name and strength (mg)
   • Quantity to compound
   • Excipients (flavoring, thickening agents)
   • Stability data expected
   • Route and frequency
6. Documentation: Record in medical record why compounding was chosen (label for drug shortage, AMDUCA compliance note)
7. Client Education: Inform owner that compounded drugs lack FDA oversight; explain expected outcomes and monitoring

Quality and Safety Concerns

• Stability: Compounded formulations typically have shorter expiration (14-90 days) vs. commercial (1-3 years)
• Bacterial Growth: Aqueous suspensions risk contamination; recommend refrigeration and use within stated period
• Accuracy: Compounding errors may occur; verify concentration before dispensing
• Interaction Risk: Excipients may interact with primary drug or other medications
• Species Validation: Ensure proposed excipients are safe for species (e.g., xylitol in dogs = toxic)

Sources

• FDA CVM AMDUCA guidance: https://www.fda.gov/animal-veterinary/guidance-documents/guidance-industry-2000
• International Journal of Pharmaceutical Compounding (industry reference)
• American Veterinary Medical Association (AVMA) Professional Liability Insurance Guidelines
• Plumb's Veterinary Drug Handbook (current edition) - compounding section
• State board of pharmacy regulations (vary by jurisdiction)

Limitations

• This skill provides regulatory and practical reference; does not replace pharmacokinetic consultation
• Compounding quality depends on pharmacist competency and facility standards
• Regional availability of 503B facilities varies significantly
• Compounded drugs lack human safety and efficacy data; veterinary discretion is mandatory